Opdualag
(Relatlimab)Phase 3Monoclonal antibody
Bristol-Myers SquibbRelatlimab is used to treat a type of skin cancer called melanoma. It works by boosting the immune system to help the body fight cancer cells.[1] Opdualag is currently being investigated across 26 indications[3], with its most advanced program in Phase 3.[1]
Opdualag is one of 570 biologic programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.
26
Indications
49
Total Trials
23
Active Trials
569
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 26 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Opdualag
Bristol-Myers SquibbPhase 3
Velban
EEastern Cooperative Oncology Group
Preclinical
Tafasitamab
IncytePreclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
VP-16
FFundamenta Therapeutics, Ltd.
Preclinical
Stem Cells
KKang Stem Biotech Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Melanoma5 trials
Nivolumab3 trials
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03607890·38 enrolled
Melanoma3 trials
Immunotherapy3 trials
Non-Small Cell Lung Cancer3 trials
28 more indications
Gastric Cancer2 trials
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT03610711·21 enrolled
Glioblastoma2 trials
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
Recruiting·—·Phase 2·NCT06816927·92 enrolled
Liver Cancer2 trials
Patients With Solid Tumors1 trial
Virus-associated Tumors1 trial
Mismatch Repair Deficiency1 trial
Basal Cell Carcinoma1 trial
Renal Cell Carcinoma1 trial
Esophageal Cancer1 trial
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT03044613·32 enrolled
Urothelial Cancer1 trial
Uveal Melanoma1 trial
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
Completed·—·Phase 2·NCT04552223·27 enrolled
Relapsed/Refractory B-cell Malignancies1 trial
Patients With Advanced Solid Tumors1 trial
Colorectal Cancer1 trial
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03642067·59 enrolled
Effectiveness1 trial
Hepatocellular Carcinoma1 trial
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT04658147·31 enrolled
Ovarian Cancer1 trial
Muscle Invasive Bladder Urothelial Carcinoma1 trial
Metastatic Nasopharyngeal Carcinoma1 trial
Lymphoma, Non-Hodgkin1 trial
Head and Neck Squamous Cell Carcinoma (HNSCC)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Relatlimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Lymphocyte Activation Gene 3 Protein Inhibitor[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company